Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191418 | 0.80 | NOS1 (0.44) | PRSS1ST14NOS1KMT2AALDH1A1 | |
| SCHEMBL3275650 | 0.79 | LOXL2 (0.44) | LOXL2F10HDAC3HDAC6NCOR2 | |
| SCHEMBL7465608 | 0.75 | LOXL2 (0.52) | LOXL2F10HDAC3HDAC6NCOR2 | |
| SCHEMBL24620530 | 0.73 | LOXL2 (0.64) | LOXL2F10HDAC3HDAC6NCOR2 | |
| SCHEMBL856509 | 0.73 | KMT2A (0.67) | LOXL2F10HDAC3HDAC6NCOR2 | |
| Hydrochloric Acid SCHEMBL7398643 | 0.71 | KMT2A (0.64) | LOXL2F10HDAC3HDAC6NCOR2 | |
| Hydrochloric Acid SCHEMBL10923292 | 0.70 | F10 (0.50) | LOXL2F10HDAC3HDAC6NCOR2 | |
| Ethylene SCHEMBL11090983 | 0.70 | KMT2A (0.61) | LOXL2F10HDAC3HDAC6NCOR2 | |
| SCHEMBL24514392 | 0.69 | LOXL2 (0.59) | LOXL2F10HDAC3HDAC6NCOR2 | |
| SCHEMBL321860 | 0.69 | LOXL2 (0.56) | LOXL2F10HDAC3HDAC6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054380-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | MEDICINES CO LEIPZIG GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8513461-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20130165510-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-8410310-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2502906-A2 | Trypsin-like serine protease inhibitors, their preparation and use | The Medicines Company (Leipzig) GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225913-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | The Medicine Company (Leipzig) GmbH (DE) | 2012-09-06 | — | — | US | disclosed |
| US-8207378-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100022781-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2054380-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | The Medicines Company (Leipzig) GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008049595-A9 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | CURACYTE DISCOVERY GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008049595-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225913-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, TFPI, SPINT2 | LOXL2 1109/4885F10 34/4885HDAC3 2984/4885 |
| US-20100022781-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, TFPI, SPINT2 | LOXL2 1052/4885F10 30/4885HDAC3 3028/4885 |
| US-20130165510-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | TFPI, SERPINE1, SPINT2 | LOXL2 1040/4885F10 38/4885HDAC3 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.